Thymidine phosphorylase in cancer aggressiveness and chemoresistance

Pharmacological Research

Volumn 132, Issue , 2018, Pages 15-20

  Furukawa, Tatsuhiko ^a   Tabata, Sho ^b   Yamamoto, Masatatsu ^a   Kawahara, Kohichi ^a   Shinsato, Yoshinari ^a   Minami, Kentaro ^a   Shimokawa, Michiko ^a   Akiyama, Shin ichi ^c  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

2 deoxy D ribose; 2 deoxy D ribose 5 phosphate aldolase; 5 FU; Angiogenesis; Capecitabine; Glycolytic pathway; NF B; ROS; TFTD; Thymidine catabolism; Thymidine phosphorylase

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; OROTATE PHOSPHORIBOSYLTRANSFERASE; THYMIDINE PHOSPHORYLASE; TIPIRACIL PLUS TRIFLURIDINE; TRANSCRIPTION FACTOR RELA; URIDINE PHOSPHORYLASE;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER PROGNOSIS; CELL MIGRATION; COLORECTAL CANCER; CYTOLOGY; CYTOTOXICITY; DRUG EFFICACY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; MEDIAN SURVIVAL TIME; METASTATIC BREAST CANCER; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OVERALL SURVIVAL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; TREATMENT RESPONSE; UPREGULATION; ANIMAL; DRUG RESISTANCE; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ANIMALS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; THYMIDINE PHOSPHORYLASE;

EID: 85044948786     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2018.03.019     Document Type: Review

References (68)

1. Akiyama, S., Furukawa, T., Sumizawa, T., Takebayashi, Y., Nakajima, Y., Shimaoka, S., Haraguchi, M., The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression. Cancer Sci. 95:11 (2004), 851–857.
2. Toi, M., Atiqur Rahman, M., Bando, H., Chow, L.W., Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol. 6:3 (2005), 158–166, 10.1016/S1470-2045(05)01766-3.
3. Liekens, S., Bronckaers, A., Perez-Perez, M.J., Balzarini, J., Targeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy. Biochem. Pharmacol. 74:11 (2007), 1555–1567, 10.1016/j.bcp.2007.05.008.
4. Bronckaers, A., Gago, F., Balzarini, J., Liekens, S., The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med. Res. Rev. 29:6 (2009), 903–953, 10.1002/med.20159.
5. Ishikawa, F., Miyazono, K., Hellman, U., Drexler, H., Wernstedt, C., Hagiwara, K., Usuki, K., Takaku, F., Risau, W., Heldin, C.H., Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 338:6216 (1989), 557–562, 10.1038/338557a0.
6. Asai, K., Nakanishi, K., Isobe, I., Eksioglu, Y.Z., Hirano, A., Hama, K., Miyamoto, T., Kato, T., Neurotrophic action of gliostatin on cortical neurons. Identity of gliostatin and platelet-derived endothelial cell growth factor. J. Biol. Chem. 267:28 (1992), 20311–20316.
7. Furukawa, T., Yoshimura, A., Sumizawa, T., Haraguchi, M., Akiyama, S., Fukui, K., Ishizawa, M., Yamada, Y., Angiogenic factor. Nature, 356(6371), 1992, 668, 10.1038/356668a0.
8. Sumizawa, T., Furukawa, T., Haraguchi, M., Yoshimura, A., Takeyasu, A., Ishizawa, M., Yamada, Y., Akiyama, S., Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor. J. Biochem. 114:1 (1993), 9–14.
9. Usuki, K., Saras, J., Waltenberger, J., Miyazono, K., Pierce, G., Thomason, A., Heldin, C.H., Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. Biochem. Biophys. Res. Commun. 184:3 (1992), 1311–1316.
10. Moghaddam, A., Bicknell, R., Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry 31:48 (1992), 12141–12146.
11. Haraguchi, M., Miyadera, K., Uemura, K., Sumizawa, T., Furukawa, T., Yamada, K., Akiyama, S., Yamada, Y., Angiogenic activity of enzymes. Nature, 368(6468), 1994, 198, 10.1038/368198a0.
12. Miyadera, K., Sumizawa, T., Haraguchi, M., Yoshida, H., Konstanty, W., Yamada, Y., Akiyama, S., Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res. 55:8 (1995), 1687–1690.
13. Matsushita, S., Nitanda, T., Furukawa, T., Sumizawa, T., Tani, A., Nishimoto, K., Akiba, S., Miyadera, K., Fukushima, M., Yamada, Y., Yoshida, H., Kanzaki, T., Akiyama, S., The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. Cancer Res. 59:8 (1999), 1911–1916.
14. Uchimiya, H., Furukawa, T., Okamoto, M., Nakajima, Y., Matsushita, S., Ikeda, R., Gotanda, T., Haraguchi, M., Sumizawa, T., Ono, M., Kuwano, M., Kanzaki, T., Akiyama, S., Suppression of thymidine phosphorylase-mediated angiogenesis and tumor growth by 2-deoxy-L-ribose. Cancer Res. 62:10 (2002), 2834–2839.
15. Fukushima, M., Suzuki, N., Emura, T., Yano, S., Kazuno, H., Tada, Y., Yamada, Y., Asao, T., Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2’-deoxyribonucleosides. Biochem. Pharmacol. 59:10 (2000), 1227–1236.
16. Bijnsdorp, I.V., Capriotti, F., Kruyt, F.A., Losekoot, N., Fukushima, M., Griffioen, A.W., Thijssen, V.L., Peters, G.J., Thymidine phosphorylase in cancer cells stimulates human endothelial cell migration and invasion by the secretion of angiogenic factors. Br. J. Cancer 104:7 (2011), 1185–1192, 10.1038/bjc.2011.74.
17. Liekens, S., Hernandez, A.I., Ribatti, D., De Clercq, E., Camarasa, M.J., Perez-Perez, M.J., Balzarini, J., The nucleoside derivative 5’-O-trityl-inosine (KIN59) suppresses thymidine phosphorylase-triggered angiogenesis via a noncompetitive mechanism of action. J. Biol. Chem. 279:28 (2004), 29598–29605, 10.1074/jbc.M402602200.
18. Reigan, P., Gbaj, A., Stratford, I.J., Bryce, R.A., Freeman, S., Xanthine oxidase-activated prodrugs of thymidine phosphorylase inhibitors. Eur. J. Med. Chem. 43:6 (2008), 1248–1260, 10.1016/j.ejmech.2007.07.015.
19. Klein, R.S., Lenzi, M., Lim, T.H., Hotchkiss, K.A., Wilson, P., Schwartz, E.L., Novel 6-substituted uracil analogs as inhibitors of the angiogenic actions of thymidine phosphorylase. Biochem. Pharmacol. 62:9 (2001), 1257–1263.
20. Liekens, S., Bronckaers, A., Belleri, M., Bugatti, A., Sienaert, R., Ribatti, D., Nico, B., Gigante, A., Casanova, E., Opdenakker, G., Perez-Perez, M.J., Balzarini, J., Presta, M., The thymidine phosphorylase inhibitor 5’-O-tritylinosine (KIN59) is an antiangiogenic multitarget fibroblast growth factor-2 antagonist. Mol. Cancer Ther. 11:4 (2012), 817–829, 10.1158/1535-7163.MCT-11-0738.
21. Hotchkiss, K.A., Ashton, A.W., Schwartz, E.L., Thymidine phosphorylase and 2-deoxyribose stimulate human endothelial cell migration by specific activation of the integrins alpha 5 beta 1 and alpha V beta 3. J. Biol. Chem. 278:21 (2003), 19272–19279, 10.1074/jbc.M212670200.
22. Seeliger, H., Guba, M., Koehl, G.E., Doenecke, A., Steinbauer, M., Bruns, C.J., Wagner, C., Frank, E., Jauch, K.W., Geissler, E.K., Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clin. Cancer Res. 10:5 (2004), 1843–1852.
23. Lechertier, T., Hodivala-Dilke, K., Focal adhesion kinase and tumour angiogenesis. J. Pathol. 226:2 (2012), 404–412, 10.1002/path.3018.
24. Takebayashi, Y., Yamada, K., Miyadera, K., Sumizawa, T., Furukawa, T., Kinoshita, F., Aoki, D., Okumura, H., Yamada, Y., Akiyama, S., Aikou, T., The activity and expression of thymidine phosphorylase in human solid tumours. Eur. J. Cancer 32A:7 (1996), 1227–1232.
25. Giatromanolaki, A., Koukourakis, M.I., Theodossiou, D., Barbatis, K., O'Byrne, K., Harris, A.L., Gatter, K.C., Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer. Clin. Cancer Res. 3:12 Pt 1 (1997), 2485–2492.
26. Takebayashi, Y., Natsugoe, S., Baba, M., Akiba, S., Fukumoto, T., Miyadera, K., Yamada, Y., Takao, S., Akiyama, S., Aikou, T., Thymidine phosphorylase in human esophageal squamous cell carcinoma. Cancer 85:2 (1999), 282–289.
27. Takao, S., Akiyama, S.I., Nakajo, A., Yoh, H., Kitazono, M., Natsugoe, S., Miyadera, K., Fukushima, M., Yamada, Y., Aikou, T., Suppression of metastasis by thymidine phosphorylase inhibitor. Cancer Res. 60:19 (2000), 5345–5348.
28. Takebayashi, Y., Akiyama, S., Akiba, S., Yamada, K., Miyadera, K., Sumizawa, T., Yamada, Y., Murata, F., Aikou, T., Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J. Natl. Cancer Inst. 88:16 (1996), 1110–1117.
29. Shimaoka, S., Matsushita, S., Nitanda, T., Matsuda, A., Nioh, T., Suenaga, T., Nishimata, Y., Akiba, S., Akiyama, S., Nishimata, H., The role of thymidine phosphorylase expression in the invasiveness of gastric carcinoma. Cancer 88:10 (2000), 2220–2227.
30. Imazano, Y., Takebayashi, Y., Nishiyama, K., Akiba, S., Miyadera, K., Yamada, Y., Akiyama, S., Ohi, Y., Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J. Clin. Oncol. 15:7 (1997), 2570–2578, 10.1200/JCO.1997.15.7.2570.
31. van Triest, B., Pinedo, H.M., Blaauwgeers, J.L., van Diest, P.J., Schoenmakers, P.S., Voorn, D.A., Smid, K., Hoekman, K., Hoitsma, H.F., Peters, G.J., Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin. Cancer Res. 6:3 (2000), 1063–1072.
32. O'Brien, T.S., Fox, S.B., Dickinson, A.J., Turley, H., Westwood, M., Moghaddam, A., Gatter, K.C., Bicknell, R., Harris, A.L., Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res. 56:20 (1996), 4799–4804.
33. Nakajima, Y., Gotanda, T., Uchimiya, H., Furukawa, T., Haraguchi, M., Ikeda, R., Sumizawa, T., Yoshida, H., Akiyama, S., Inhibition of metastasis of tumor cells overexpressing thymidine phosphorylase by 2-deoxy-L-ribose. Cancer Res. 64:5 (2004), 1794–1801.
34. Nakajima, Y., Haraguchi, M., Furukawa, T., Yamamoto, M., Nakanishi, H., Tatematsu, M., Akiyama, S., 2-Deoxy-L-ribose inhibits the invasion of thymidine phosphorylase-overexpressing tumors by suppressing matrix metalloproteinase-9. Int. J. Cancer 119:7 (2006), 1710–1716, 10.1002/ijc.22014.
35. Kitadai, Y., Haruma, K., Mukaida, N., Ohmoto, Y., Matsutani, N., Yasui, W., Yamamoto, S., Sumii, K., Kajiyama, G., Fidler, I.J., Tahara, E., Regulation of disease-progression genes in human gastric carcinoma cells by interleukin 8. Clin. Cancer Res. 6:7 (2000), 2735–2740.
36. Tabata, S., Ikeda, R., Yamamoto, M., Shimaoka, S., Mukaida, N., Takeda, Y., Yamada, K., Soga, T., Furukawa, T., Akiyama, S., Thymidine phosphorylase activates NFkappaB and stimulates the expression of angiogenic and metastatic factors in human cancer cells. Oncotarget 5:21 (2014), 10473–10485, 10.18632/oncotarget.2242.
37. de Bruin, M., Peters, G.J., Oerlemans, R., Assaraf, Y.G., Masterson, A.J., Adema, A.D., Dijkmans, B.A., Pinedo, H.M., Jansen, G., Sulfasalazine down-regulates the expression of the angiogenic factors platelet-derived endothelial cell growth factor/thymidine phosphorylase and interleukin-8 in human monocytic-macrophage THP1 and U937 cells. Mol. Pharmacol. 66:4 (2004), 1054–1060, 10.1124/mol.104.000315.
38. Ashizawa, T., Okada, R., Suzuki, Y., Takagi, M., Yamazaki, T., Sumi, T., Aoki, T., Ohnuma, S., Aoki, T., Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 8:2 (2005), 124–131, 10.1007/s10120-005-0315-x.
39. Lin, M.T., Lin, B.R., Chang, C.C., Chu, C.Y., Su, H.J., Chen, S.T., Jeng, Y.M., Kuo, M.L., IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway. Int. J. Cancer 120:12 (2007), 2600–2608, 10.1002/ijc.22599.
40. Kamoshida, G., Matsuda, A., Miura, R., Takashima, Y., Katsura, A., Tsuji, T., Potentiation of tumor cell invasion by co-culture with monocytes accompanying enhanced production of matrix metalloproteinase and fibronectin. Clin. Exp. Metastasis 30:3 (2013), 289–297, 10.1007/s10585-012-9536-7.
41. Brown, N.S., Jones, A., Fujiyama, C., Harris, A.L., Bicknell, R., Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res. 60:22 (2000), 6298–6302.
42. Tabata, S., Ikeda, R., Yamamoto, M., Furukawa, T., Kuramoto, T., Takeda, Y., Yamada, K., Haraguchi, M., Nishioka, Y., Sone, S., Akiyama, S., Thymidine phosphorylase enhances reactive oxygen species generation and interleukin-8 expression in human cancer cells. Oncol. Rep. 28:3 (2012), 895–902, 10.3892/or.2012.1887.
43. Backos, D.S., Fritz, K.S., McArthur, D.G., Kepa, J.K., Donson, A.M., Petersen, D.R., Foreman, N.K., Franklin, C.C., Reigan, P., Glycation of glutamate cysteine ligase by 2-deoxy-d-ribose and its potential impact on chemoresistance in glioblastoma. Neurochem. Res. 38:9 (2013), 1838–1849, 10.1007/s11064-013-1090-4.
44. Haraguchi, M., Furukawa, T., Sumizawa, T., Akiyama, S., Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites. Cancer Res. 53:23 (1993), 5680–5682.
45. Schwartz, E.L., Baptiste, N., Wadler, S., Makower, D., Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J. Biol. Chem. 270:32 (1995), 19073–19077.
46. Temmink, O.H., de Bruin, M., Turksma, A.W., Cricca, S., Laan, A.C., Peters, G.J., Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines. Int. J. Biochem. Cell Biol. 39:3 (2007), 565–575, 10.1016/j.biocel.2006.10.009.
47. Cao, D., Pizzorno, G., Uridine phosophorylase: an important enzyme in pyrimidine metabolism and fluoropyrimidine activation. Drugs Today 40:5 (2004), 431–443.
48. Bijnsdorp, I.V., Azijli, K., Jansen, E.E., Wamelink, M.M., Jakobs, C., Struys, E.A., Fukushima, M., Kruyt, F.A., Peters, G.J., Accumulation of thymidine-derived sugars in thymidine phosphorylase overexpressing cells. Biochem. Pharmacol. 80:6 (2010), 786–792, 10.1016/j.bcp.2010.05.009.
49. Yasuno, H., Kurasawa, M., Yanagisawa, M., Sato, Y., Harada, N., Mori, K., Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes. Oncol. Rep. 29:2 (2013), 451–458, 10.3892/or.2012.2149.
50. Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., Ishitsuka, H., Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer 34:8 (1998), 1274–1281.
51. Hoff, P.M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., Burger, H.U., Osterwalder, B., Wong, A.O., Wong, R., Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J. Clin. Oncol. 19:8 (2001), 2282–2292, 10.1200/JCO.2001.19.8.2282.
52. Kobashi, N., Matsumoto, H., Zhao, S., Meike, S., Okumura, Y., Abe, T., Akizawa, H., Ohkura, K., Nishijima, K., Tamaki, N., Kuge, Y., The thymidine phosphorylase imaging agent 123I-IIMU predicts the efficacy of capecitabine. J. Nucl. Med. 57:8 (2016), 1276–1281, 10.2967/jnumed.115.165811.
53. Puglisi, F., Andreetta, C., Valent, F., Minisini, A.M., Rijavec, E., Russo, S., Mansutti, M., Cardellino, G., Pizzolitto, S., Di Loreto, C., Anthracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells. Anticancer Drugs 18:8 (2007), 883–888, 10.1097/CAD.0b013e32816ebede.
54. Puglisi, F., Cardellino, G.G., Crivellari, D., Di Loreto, C., Magri, M.D., Minisini, A.M., Mansutti, M., Andreetta, C., Russo, S., Lombardi, D., Perin, T., Damante, G., Veronesi, A., Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer. Ann. Oncol. 19:9 (2008), 1541–1546, 10.1093/annonc/mdn165.
55. Andreetta, C., Puppin, C., Minisini, A., Valent, F., Pegolo, E., Damante, G., Di Loreto, C., Pizzolitto, S., Pandolfi, M., Fasola, G., Piga, A., Puglisi, F., Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. Ann. Oncol. 20:2 (2009), 265–271, 10.1093/annonc/mdn592.
56. Gligorov, J., Doval, D., Bines, J., Alba, E., Cortes, P., Pierga, J.Y., Gupta, V., Costa, R., Srock, S., de Ducla, S., Freudensprung, U., Mustacchi, G., Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trialt. Lancet Oncol. 15:12 (2014), 1351–1360, 10.1016/S1470-2045(14)70444-9.
57. Bonotto, M., Fontanella, C., Puglisi, F., Looking for predictive markers in breast cancer. Lancet Oncol., 16(1), 2015, e1, 10.1016/S1470-2045(14)71107-6.
58. Matsuoka, K., Iimori, M., Niimi, S., Tsukihara, H., Watanabe, S., Kiyonari, S., Kiniwa, M., Ando, K., Tokunaga, E., Saeki, H., Oki, E., Maehara, Y., Kitao, H., Trifluridine induces p53-dependent sustained G2 phase arrest with its massive misincorporation into DNA and few DNA strand Breaks. Mol. Cancer Ther. 14:4 (2015), 1004–1013, 10.1158/1535-7163.MCT-14-0236.
59. de Bruin, M., Smid, K., Laan, A.C., Noordhuis, P., Fukushima, M., Hoekman, K., Pinedo, H.M., Peters, G.J., Rapid disappearance of deoxyribose-1-phosphate in platelet derived endothelial cell growth factor/thymidine phosphorylase overexpressing cells. Biochem. Biophys. Res. Commun. 301:3 (2003), 675–679.
60. Mayer, R.J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., Sobrero, A., Boucher, E., Peeters, M., Tran, B., Lenz, H.J., Zaniboni, A., Hochster, H., Cleary, J.M., Prenen, H., Benedetti, F., Mizuguchi, H., Makris, L., Ito, M., Ohtsu, A., Group, R.S., Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 372:20 (2015), 1909–1919, 10.1056/NEJMoa1414325.
61. Brown, N.S., Bicknell, R., Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem. J. 334:Pt 1 (1998), 1–8.
62. Tabata, S., Yamamoto, M., Goto, H., Hirayama, A., Ohishi, M., Kuramoto, T., Mitsuhashi, A., Ikeda, R., Haraguchi, M., Kawahara, K., Shinsato, Y., Minami, K., Saijo, A., Hanibuchi, M., Nishioka, Y., Sone, S., Esumi, H., Tomita, M., Soga, T., Furukawa, T., Akiyama, S.I., Thymidine catabolism as a metabolic strategy for cancer survival. Cell Rep. 19:7 (2017), 1313–1321, 10.1016/j.celrep.2017.04.061.
63. Hoffee, P.A., 2-Deoxyribose gene-enzyme complex in Salmonella typhimurium. I. Isolation and enzymatic characterization of 2-deoxyribose-negative mutants. J. Bacteriol. 95:2 (1968), 449–457.
64. Sgarrella, F., Poddie, F.P., Meloni, M.A., Sciola, L., Pippia, P., Tozzi, M.G., Channelling of deoxyribose moiety of exogenous DNA into carbohydrate metabolism: role of deoxyriboaldolase. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 117:2 (1997), 253–257.
65. Haraguchi, M., Tsujimoto, H., Fukushima, M., Higuchi, I., Kuribayashi, H., Utsumi, H., Nakayama, A., Hashizume, Y., Hirato, J., Yoshida, H., Hara, H., Hamano, S., Kawaguchi, H., Furukawa, T., Miyazono, K., Ishikawa, F., Toyoshima, H., Kaname, T., Komatsu, M., Chen, Z.S., Gotanda, T., Tachiwada, T., Sumizawa, T., Miyadera, K., Osame, M., Yoshida, H., Noda, T., Yamada, Y., Akiyama, S., Targeted deletion of both thymidine phosphorylase and uridine phosphorylase and consequent disorders in mice. Mol. Cell. Biol. 22:14 (2002), 5212–5221.
66. Hirayama, A., Kami, K., Sugimoto, M., Sugawara, M., Toki, N., Onozuka, H., Kinoshita, T., Saito, N., Ochiai, A., Tomita, M., Esumi, H., Soga, T., Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 69:11 (2009), 4918–4925, 10.1158/0008-5472.CAN-08-4806.
67. Satoh, K., Yachida, S., Sugimoto, M., Oshima, M., Nakagawa, T., Akamoto, S., Tabata, S., Saitoh, K., Kato, K., Sato, S., Igarashi, K., Aizawa, Y., Kajino-Sakamoto, R., Kojima, Y., Fujishita, T., Enomoto, A., Hirayama, A., Ishikawa, T., Taketo, M.M., Kushida, Y., Haba, R., Okano, K., Tomita, M., Suzuki, Y., Fukuda, S., Aoki, M., Soga, T., Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC. Proc. Natl. Acad. Sci. U. S. A. 114:37 (2017), E7697–E7706, 10.1073/pnas.1710366114.
68. Salleron, L., Magistrelli, G., Mary, C., Fischer, N., Bairoch, A., Lane, L., DERA is the human deoxyribose phosphate aldolase and is involved in stress response. Biochim. Biophys. Acta 1843:12 (2014), 2913–2925, 10.1016/j.bbamcr.2014.09.007.